RVRC
Revium Rx.
Price Chart
Latest Quote
$1.67
| Previous Close | $1.67 |
| Open | $1.67 |
| Day High | $1.67 |
| Day Low | $1.67 |
| Volume | 30 |
Stock Information
| Shares Outstanding | 60.73M |
| Total Debt | $152K |
| Cash Equivalents | $2.14M |
| Net Income | $-13.54M |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | $101.42M |
| EPS (TTM) | $-4.72 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $99.43M |
| Income | $-13.54M |
| Book/sh | $0.10 |
| Cash/sh | $0.04 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.62 |
| Debt/Eq | 2.47 |
Returns & Margins
| ROA | -15.63% |
| ROE | -105.91% |
Ownership
| Insider Ownership | 56.70% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 16.53 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.67 |
| SMA50 | $1.67 |
| SMA200 | $1.11 |
| RSI | nan |
| Shares Float | 22.29M |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +11.33% |
| 6 Months | +221.15% |
| YTD | +221.15% |
| Year | +234.00% |
| 3 Years | +12.08% |
| 5 Years | +32.54% |
| 10 Years | +122.67% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $1.67 | 0 |
| 2026-06-12 | $1.67 | 0 |
| 2026-06-11 | $1.67 | 0 |
| 2026-06-10 | $1.67 | 0 |
| 2026-06-09 | $1.67 | 0 |
| 2026-06-08 | $1.67 | 0 |
| 2026-06-05 | $1.67 | 0 |
| 2026-06-04 | $1.67 | 0 |
| 2026-06-03 | $1.67 | 0 |
| 2026-06-02 | $1.67 | 0 |
| 2026-06-01 | $1.67 | 0 |
| 2026-05-29 | $1.67 | 0 |
| 2026-05-28 | $1.67 | 0 |
| 2026-05-27 | $1.67 | 0 |
| 2026-05-26 | $1.67 | 0 |
| 2026-05-22 | $1.67 | 0 |
| 2026-05-21 | $1.67 | 0 |
| 2026-05-20 | $1.67 | 0 |
| 2026-05-19 | $1.67 | 0 |
| 2026-05-18 | $1.67 | 0 |
About Revium Rx.
Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mupirocin, a NLP-based formulation of potent antibiotic mupirocin. In addition, the company develops nanoparticles-based formulation of an angiotensin receptor blockers; novel adjunct for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx. was incorporated in 1997 and is headquartered in Herzliya, Israel.
